Canada Life’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,200
| Closed | -$121K | – | 2250 |
|
|
2023
Q2 | $121K | Sell |
6,200
-6,116
| -50% | -$145K | ﹤0.01% | 1899 |
|
|
2023
Q1 | $349K | Buy |
12,316
+1,151
| +10% | +$34.2K | ﹤0.01% | 1785 |
|
|
2022
Q4 | $326K | Hold |
11,165
| – | – | ﹤0.01% | 1804 |
|
|
2022
Q3 | $295K | Buy |
11,165
+128
| +1% | +$4.7K | ﹤0.01% | 1781 |
|
|
2022
Q2 | $490K | Buy |
11,037
+857
| +8% | +$39.4K | ﹤0.01% | 1676 |
|
|
2022
Q1 | $517K | Buy |
10,180
+686
| +7% | +$32.9K | ﹤0.01% | 1703 |
|
|
2021
Q4 | $484K | Sell |
9,494
-147
| -2% | -$7.62K | ﹤0.01% | 1712 |
|
|
2021
Q3 | $541K | Hold |
9,641
| – | – | ﹤0.01% | 1715 |
|
|
2021
Q2 | $412K | Hold |
9,641
| – | – | ﹤0.01% | 1781 |
|
|
2021
Q1 | $402K | Sell |
9,641
-1,909
| -17% | -$88.6K | ﹤0.01% | 1795 |
|
|
2020
Q4 | $538K | Sell |
11,550
-650
| -5% | -$30.4K | ﹤0.01% | 1729 |
|
|
2020
Q3 | $518K | Sell |
12,200
-461
| -4% | -$20.2K | ﹤0.01% | 1664 |
|
|
2020
Q2 | $608K | Sell |
12,661
-1,014
| -7% | -$50.6K | ﹤0.01% | 1634 |
|
|
2020
Q1 | $629K | Buy |
13,675
+1,017
| +8% | +$51K | ﹤0.01% | 1515 |
|
|
2019
Q4 | $754K | Buy |
+12,658
| New | +$755K | ﹤0.01% | 1600 |
|
|
2019
Q3 | – | Sell |
-14,493
| Closed | -$806K | – | 2378 |
|
|
2019
Q2 | $806K | Sell |
14,493
-716
| -5% | -$37.3K | ﹤0.01% | 1630 |
|
|
2019
Q1 | $767K | Buy |
15,209
+1,261
| +9% | +$56.1K | ﹤0.01% | 1492 |
|
|
2018
Q4 | $518K | Hold |
13,948
| – | – | ﹤0.01% | 1664 |
|
|
2018
Q3 | $967K | Buy |
13,948
+3,300
| +31% | +$250K | ﹤0.01% | 1538 |
|
|
2018
Q2 | $806K | Hold |
10,648
| – | – | ﹤0.01% | 1611 |
|
|
2018
Q1 | $561K | Sell |
10,648
-898
| -8% | -$52.2K | ﹤0.01% | 1703 |
|
|
2017
Q4 | $617K | Hold |
11,546
| – | – | ﹤0.01% | 1670 |
|
|
2017
Q3 | $678K | Hold |
11,546
| – | – | ﹤0.01% | 1646 |
|
|
2017
Q2 | $910K | Buy |
11,546
+302
| +3% | +$24.7K | ﹤0.01% | 1552 |
|
|
2017
Q1 | $932K | Buy |
11,244
+981
| +10% | +$72.9K | ﹤0.01% | 1534 |
|
|
2016
Q4 | $814K | Sell |
10,263
-530
| -5% | -$38.5K | ﹤0.01% | 1557 |
|
|
2016
Q3 | $755K | Buy |
10,793
+9,861
| +1,058% | +$546K | ﹤0.01% | 1544 |
|
|
2016
Q2 | $36K | Hold |
932
| – | – | ﹤0.01% | 2385 |
|
|
2016
Q1 | $38K | Hold |
932
| – | – | ﹤0.01% | 2218 |
|
|
2015
Q4 | $83K | Hold |
932
| – | – | ﹤0.01% | 1891 |
|
|
2015
Q3 | $69K | Buy |
+932
| New | +$77.5K | ﹤0.01% | 1941 |
|
Other funds holding EGRX
BIP
Canada Life's EGRX Position: Q3 2023 in Review
Canada Life sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 6,200 shares — an estimated $121K sold.
Canada Life first reported a position in EGRX in Q3 2015 and held it in 31 quarters. The position peaked at $967K in Q3 2018. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.
- Canada Life reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Canada Life sold 6,200 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $121K.
- Canada Life first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 31 quarters.
- Canada Life's Eagle Pharmaceuticals, Inc. position peaked at $967K in Q3 2018.
- 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.
Based on Canada Life's 13F filing for Q3 2023, filed 14 Nov 2023.